NASDAQ
No price data available for this timeframe.
ADMA Biologics, Inc. (ADMA) has a consensus Buy rating from 10 analysts with an average price target of $21.00, representing +144.8% upside from the current price of $8.58.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Jun 10, 2026 | Ryan Deschner | Raymond James | $21.00 | $8.12 | +158.62% |
| May 7, 2026 | Gary Nachman | Canaccord Genuity | $18.00 | $10.08 | +78.57% |
| Apr 20, 2026 | Unknown | Canaccord Genuity | $21.00 | $10.88 | +93.01% |
| Apr 13, 2026 | Anthony Petrone | Mizuho Securities | $24.00 | $10.33 |
May 7, 2026 | Maintained | Canaccord Genuity | Buy | Buy |
May 7, 2026 | Maintained | Mizuho | Outperform | Outperform |
Apr 13, 2026 | Maintained | Mizuho | Outperform | Outperform |
Mar 26, 2026 | Downgrade | Cantor Fitzgerald | Overweight | Neutral |
May 8, 2025 | Maintained | Raymond James | Strong Buy | Strong Buy |
| +132.33% |
| Oct 14, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $17.14 | +4.99% |